WO2000010977A1 - Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles - Google Patents

Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles Download PDF

Info

Publication number
WO2000010977A1
WO2000010977A1 PCT/US1999/018998 US9918998W WO0010977A1 WO 2000010977 A1 WO2000010977 A1 WO 2000010977A1 US 9918998 W US9918998 W US 9918998W WO 0010977 A1 WO0010977 A1 WO 0010977A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
heterocycle
group
substituted
alkali salt
Prior art date
Application number
PCT/US1999/018998
Other languages
French (fr)
Other versions
WO2000010977A9 (en
Inventor
K. Barry Sharpless
Lukas J. Goossen
Hong Liu
Klaus R. Dress
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Priority to AU56822/99A priority Critical patent/AU5682299A/en
Publication of WO2000010977A1 publication Critical patent/WO2000010977A1/en
Publication of WO2000010977A9 publication Critical patent/WO2000010977A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Definitions

  • the present invention relates to the aminohydroxylation of olefins. More particularly, the present invention relates to the use of amino-substituted heterocycles as a nitrogen source for enantioselective aminohydroxylation reactions.
  • a new generation of nitrogen sources is disclosed which greatly extends the scope of the osmium-catalyzed asymmetric aminohydroxylation (AA). With these nitrogen souices, the AA can now be considered as a means for introducing complex heterocyclic fragments into hydrocarbon backbones when approp ⁇ ate olefinic functionality is present.
  • One aspect of the invention is directed to an improved method for converting an olefin to a ⁇ -aminoalcohol using an osmium-catalyzed asymmetric aminohydroxylation reaction.
  • the olefin is enantioselectively aminohydroxylated using chiral hgands and an N-halo alkali salt of an ammo-substituted heterocycle as a nitrogen source for producing the ⁇ -aminoalcohol.
  • the ammo group of the amino-substituted heterocycle is oxidized to form the N-halo alkali salt.
  • the heterocycle of the ammo- substituted heterocycle includes a ring lmine conjugated with the amino group to form a planar imidamide system.
  • the ⁇ -aminoalcohol produced by the catalytic asymmetric aminohydroxylation reaction has a ⁇ -amino group substituted with the heterocycle.
  • the N-halo alkali salt of the amino-substituted heterocycle is represented by the following structure:
  • X is a halogen
  • Z + is an alkali counter ion
  • -( ⁇ -X) " Z + represents the N-halo alkali salt
  • -R 1 is one or more radicals, each independently selected from of hydrogen, halogen, aryl, and alkyl groups.
  • Y does not include a fused imidazole ring that is coplanar with the planar imidamide system.
  • the N-halo alkali salt of the amino-substituted heterocycle is obtained by oxidation of the following amino-substituted heterocycles:
  • each R is independently selected from hydrogen, halogen, alkyl, aryl or, together with an adjacent R group, forms a fused aromatic ring.
  • Figure 1 illustrates an aminohydroxylation with a generalized amino-substituted heterocycle.
  • Figure 2 illustrates the aminohydroxylation with exemplary amino-substituted heterocycles.
  • Figure3 illustrates the aminohydroxylation of stilbene with various amino- substituted-heterocycles. Footnotes therein are as follows: [a] Major product from the reaction using (DHQ) 2 PHAL. [b] Isolated yields of pure products after chromatography on silica gel. [c] Determined by chiral HPLC. [d] Concentration in grams per 100 mL of EtOH/CHCl 3 1:1.
  • Figure 4 illustrates the aminohydroxylation of various olefins with 2-amino-4,6- dimethyltriazine. Footnotes therein are as follows: [a] Major product from the reaction using (DHQ) 2 PHAL. [b] Determined by ⁇ NMR spectroscopy. [c] Determined by chiral HPLC. [d] Isolated yields from the reaction using the (DHQ) 2 PHAL ligand, where regioisomers are possible, of mixture of both regioisomers. Similar yields and regioselectivities were obtained with the (DHQD) 2 PHAL ligand.

Abstract

Amino-substituted heterocycles are disclosed to be suitable nitrogen sources for the osmium catalyzed asymmetric aminohydroxylation of olefins, achieving suprafacial, vicinal addition of a heterocycle moiety and a hydroxyl group. The enantioselectivities are strongly dependent on the nature of the heterocycles and are comparable to those of standard nitrogen sources. Instead of merely providing a route to protected aminoalcohols, the AA can now also be considered as a means to introduce complex substructures to hydrocarbon backbones.

Description

CATALYTIC ASYMMETRIC AMINOHYDROXYLATION WITH AMINO-SUBSTITUTED HETEROCYCLES
Description
Government Rights:
This invention was made with government support under Grant No. GM-28384 awarded by the National Institutes of Health and with government support under Grant No. CHE-9531152 awarded by the National Science Foundation. The U.S. government has certain rights in the invention.
Technical Field:
The present invention relates to the aminohydroxylation of olefins. More particularly, the present invention relates to the use of amino-substituted heterocycles as a nitrogen source for enantioselective aminohydroxylation reactions.
Background:
The β-aminoalcohol moiety appears in numerous biologically active compounds (G. Shaw in Comprehensive Heterocyclic Chemistry II, Vol. 7 (Eds.: A. R. Katritzky, C. W. Rees, E. F. V. Scriven), Pergamon, New York, 1996, pp. 397 - 429). To this end, the osmium-catalyzed asymmetric aminohydroxylation (AA) of olefins provides an efficient method for the enantioselective creation of this important functionality (G. Schlingloff, et al., in Asymmetric Oxidation Reactions: A Practical Approach (Ed.: T. Katsuki), Oxford University Press, Oxford, 1998; and H. C. Kolb, et al., in Transition Metals for Fine Chemicals and Organic Synthesis, Vol. 2 (Eds.: M. Beller, C. Bolm), Wiley- VCH, New York, 1998, pp. 243 - 260). A number of nitrogen sources have been employed for the AA reaction. Sulfonamides were one of the first nitrogen sources to be employed in the AA reaction (G. Li, et al., Angew. Chem. Int. Ed. Engl. 1996, 35, 451 - 454). Subsequent to this initial report, there has been rapid improvement in both scope and selectivity. The use of amides as a nitrogen source was reported by M. Bruncko et al. (Angew. Chem. Int. Ed. Engl. 1997, 36, 1483 - 1486). The use of carbamates was reported by G. Li et al. (Angew. Chem. Int. Ed. Engl. 1996, 35, 2813 - 2815) and by K. L. Reddy et al. ( J. Am. Chem. Soc. 1998, 120, 1207 - 1217). The N-protected aminoalcohols obtained were usually converted to free aminoalcohols so that the development of a set of orthogonally cleavable protecting groups had been a major concern Current developments in combinatorial chemistry have stimulated the exploitation of this reaction for the direct introduction of biomedically relevant heterocyclic substructures to olefins. (F Balkenhohl, et al. Angew Chem. Int. Ed. Engl. 1996, 35, 2288 - 2337; and A Νefzi, et al Chem. Rev. 1997, 97, 449 - 472).
Attempts to extend the scope of the nitrogen sources in the AA to heterocyclic compounds had long been frustrated by very poor turnover and side reactions, e g. πng chloπnations (I Lengyel, et al , Synth Commun 1998, 28, 1891 - 1896, and references therein) This problem was then solved by Jeπna et al , when a breakthrough was achieved with the use of an adenine derivative as nitrogen source in the aminohydroxylation of a unique olefin (A. S Pilcher, et al., J. Am. Chem. Soc. 1998, 120, 3520 - 3521) Subsequently, a general procedure for this kind of transformation was developed (K R Dress, et al , Tetrahedron Lett 1998, 39, 7669 - 7672). However, no asymmetric inductions weie achieved.
Summary:
A new generation of nitrogen sources is disclosed which greatly extends the scope of the osmium-catalyzed asymmetric aminohydroxylation (AA). With these nitrogen souices, the AA can now be considered as a means for introducing complex heterocyclic fragments into hydrocarbon backbones when appropπate olefinic functionality is present.
One aspect of the invention is directed to an improved method for converting an olefin to a β-aminoalcohol using an osmium-catalyzed asymmetric aminohydroxylation reaction. More particularly, the olefin is enantioselectively aminohydroxylated using chiral hgands and an N-halo alkali salt of an ammo-substituted heterocycle as a nitrogen source for producing the β-aminoalcohol. The ammo group of the amino-substituted heterocycle is oxidized to form the N-halo alkali salt. The heterocycle of the ammo- substituted heterocycle includes a ring lmine conjugated with the amino group to form a planar imidamide system. The β-aminoalcohol produced by the catalytic asymmetric aminohydroxylation reaction has a β-amino group substituted with the heterocycle. The N-halo alkali salt of the amino-substituted heterocycle is represented by the following structure:
Figure imgf000005_0001
In the above structure, X is a halogen; Z+ is an alkali counter ion; -(Ν-X)" Z+ represents the N-halo alkali salt, Ν=C represents the ring imine; N=C-N represents the planar imidamide system; Y together with the ring imine forms the heterocycle; and -R1 is one or more radicals, each independently selected from of hydrogen, halogen, aryl, and alkyl groups. However, there is a proviso that Y does not include a fused imidazole ring that is coplanar with the planar imidamide system. It has been found that the sp2 nitrogen of fused imidazole rings coplanar with the planar imidamide system coordinate with the osmium during catalysis and block or inhibit the enantioselective activity of chiral ligands. In a preferred mode, the N-halo alkali salt of the amino-substituted heterocycle is obtained by oxidation of the following amino-substituted heterocycles:
Figure imgf000006_0001
In the above structures, each R is independently selected from hydrogen, halogen, alkyl, aryl or, together with an adjacent R group, forms a fused aromatic ring.
Brief Description of Drawings:
Figure 1 illustrates an aminohydroxylation with a generalized amino-substituted heterocycle. Figure 2 illustrates the aminohydroxylation with exemplary amino-substituted heterocycles.
Figure3 illustrates the aminohydroxylation of stilbene with various amino- substituted-heterocycles. Footnotes therein are as follows: [a] Major product from the reaction using (DHQ)2PHAL. [b] Isolated yields of pure products after chromatography on silica gel. [c] Determined by chiral HPLC. [d] Concentration in grams per 100 mL of EtOH/CHCl3 1:1.
Figure 4 illustrates the aminohydroxylation of various olefins with 2-amino-4,6- dimethyltriazine. Footnotes therein are as follows: [a] Major product from the reaction using (DHQ)2PHAL. [b] Determined by Η NMR spectroscopy. [c] Determined by chiral HPLC. [d] Isolated yields from the reaction using the (DHQ)2PHAL ligand, where regioisomers are possible, of mixture of both regioisomers. Similar yields and regioselectivities were obtained with the (DHQD)2PHAL ligand.
Detailed Description:
Disclosed herein is an enantioselective procedure for the vicinal addition of a hydroxyl group and amino-substituted heterocycles to olefins (Scheme 1).
Figure imgf000007_0001
Scheme 1 Aminohydroxylation with aminosubstituted heterocycles; Het = heterocycle.
J. Rudolph, et al. disclosed that the size and particular placement of the heteroatoms in the adenine moiety favor "second cycle turnover"( Angew. Chem. Int. Ed. Engl. 1996, 35, 2810 - 2813). This would preclude the desired chirality transfer from the alkaloid ligand. Contrary to this teaching, it is disclosed herein that simple aminopyrimidines and aminotriazines function as excellent reagents for the asymmetric aminohydroxylation. With a few modifications to the original procedure, stilbene is converted to either enantiomer of the corresponding aminoalcohol in high ee with 2- aminopyrimidine as the nitrogen source (Scheme 2). 1. βuOCI, EtOH, 0βC 2. aq. NaOH, 0°C
Figure imgf000008_0002
Figure imgf000008_0001
Scheme 2 Aminohydroxylation of traπs-stilbene with 2-aminopyrimidine.
It is imperative that the N-chlorination be performed in the absence of water to retard the electrophilic aromatic substitution. Deprotonation with aqueous ΝaOH affords the chloramine salts, which are relatively stable, especially under an inert atmosphere. A slight deficit of ΝaOH ensured the absence of excess OH even if some chloramine had been consumed by side reactions. The only suitable solvent systems turned out to be mixtures of primary alcohols and water (approx. 2: 1 ratio). No turnover was observed for mixtures of water and acetonitrile or tert-butanol. The use of highly polar protic solvents appears crucial to facilitate the rate of hydrolysis of the relatively electron rich osmium azaglycolate intermediate. Stilbene was chosen as an ideal test olefin for probing the reactivity of other heterocycles because of the mediocre enantioselectivities observed with standard nitrogen sources. The results are documented in Figure 3.
The enantiomeric excesses of 56 to 97% observed with these heterocyclic nitrogen sources are quite impressive when compared to earlier nitrogen sources for the AA. For instance, 62% ee with Chloramine-T (ibid, G. Li, et al. 1996); 75% ee with Chloramine-M (ibid, J. Rudolph, et al. 1996); 94% ee with N-bromoacetamide (ibid, M. Bruncko, et al. 1997); 91% ee with N-halocarbarmate, as disclosed by G. Li (ibid, G. Li 1996). The ee depends on both steric and electronic characteristics of the heterocycles. Smaller nitrogen sources seem to provide higher enantiomeric excesses than the more sterically demanding systems (entry 1, 2 versus 3, 5). There seems to be a modest ee advantage for less electron withdrawing substituents on the nitrogen (entry 1, 3 versus 2, 5). The chemical yields are reasonable to good, with ring chlorinated aminoalcohols as the major contaminants, e.g., entry 1 where 23% of aminoalcohol derived from 2-amino-5-chloropyrimidine was isolated. In order to map out the scope of this reaction on the olefin side, we screened a number of representative olefins with 2-amino-4,6-dimethyl-l,3,5-triazine as a nitrogen source, for the simple reason that it had shown midrange enantioselectivity with stilbene. A remarkably broad range of olefins gave good yields and enantioselectivities (Figure 4) when subjected to the reaction conditions. Cinnamate and fumarate (entry 1, 2) are among the best substrates, whereas the enantioselectivity for the trisubstituted olefin (entry 5) remains poor. In contrast to the highly regioselective adenine derivatives (ibid, K. R. Dress, 1998) , the simple heterocyclic nitrogen sources give modest regioselectivities, comparable to that of the earlier versions of the AA. For all unsymmetrical olefins, a strong preference for the isomer with nitrogen in the benzylic position was observed; isopropyl cinnamate gave only a single regioisomer. The regioisomers were separable by preparative TLC.
Experimental Section Representative procedure for the aminohydroxylations: Reaction of 2- aminopyrimidine with tra/ts-stilbene. All solvents were deoxygenated by three freeze pump / thaw cycles under nitrogen, all reactions were performed under an argon atmosphere. 2-aminopyrimidine (95.1 g mol"1, 166 mg, 1.75 mmol) was dissolved in dry ethanol (20.0 mL). The solution was cooled in an ice bath. tert-Butylhypochlorite (108.5 g mol"1, 190 mg, 1.75 mmol) was added. The solution was allowed to warm up to RT and was stirred for 30 min. Then it was cooled again to 0 °C and aqueous NaOH (1.00 M, 1.50 mL, 1.50 mmol) was added. The solution was again warmed to RT in a water bath and water (8.5 mL) was added. Finely divided trans-stilbene (180.2 g mol~l, 90.1 mg, 0.50 mmol), (DHQ)2PHAL (778 g mol"1, 23.3 mg, 30 μmol, 6 mol%), and K2OsO2(OH)4 (368 g mol"1, 9.2 mg, 25 μmol, 5 mol%) were added. The mixture was stirred at RT for 12 h. A saturated solution of NaHSO3 (4 mL) and water (10 mL) was added and the mixture was stirred for 1 h at RT. The mixture was then placed in a separatory funnel and EtOAc (80 mL) was added. The organic phase was separated and washed with water (40 mL) and brine (40 mL). After drying over MgSO4, the solvent was evaporated to leave a brownish residue. The product was purified by column chromatography (SiO2, CH2Cl2/MeOH, 1-
5%) yielding 66 mg (45%) as an off-white solid. As a second band, small quantities of the corresponding ring chlorinated product were isolated. Melting point: 132°C (decomp); HRMS (FAB) [C18H17N3O] calcd. for MH+ 292.1450, found 292.1460; Η NMR (400 MHz, CDClj, 25°C, TMS): δ=8.12 (d, V(H,H) = 8 Hz, 2H, N=CH), 7.37 - 7.21 (m, 10H, Ph-CH), 6.45 (t, 3J(H,H) = 8 Hz, 1H, py-CH), 6.28 (br d, V(H,H) = 13 Hz, 1H, NH), 5.29 (dd, V(H,H) = 13, 7 Hz, 1H, CHN), 5.07 (d, 37(H,H) = 7 Hz, 2H, CHO), 4.08 (s, 1H, OH) ppm; 13C NMR (100 MHz, CDC13): δ = 162.2, 157.9, 141.4, 140.5, 128.5, 128.1, 127.5, 127.4, 127.1, 126.4, 111.0, 78.0, 61.7 ppm; [α]20 D = - 0.7° (c = 0.59, in EtOH/CHCl3 1:1, α = -0.4 °); HPLC: Chiralpak AS, 30% iPrOH/hexane, 1 mL min, 5.1 min (IS, 25), 7.2 (1R, 2R).
Assignment of the absolute configuation: (15, 25)-2-Amino-l,2-diphenylethanol was converted to an authentic sample of the (15, 25) enantiomer mentioned above by reaction with 2-bromopyrimidine (C. G. Overberger, et al., Org. Synth. Coll. Vol. 7V 1963, 336 - 337).
All other compounds were produced similarly. Regioisomers were usually separable by preparative TLC. It is advisable to keep the solvent polarity as high as possible, however, for some nonpolar olefins the addition of a small quantity of π-propanol was necessary to ensure the formation of homogeneous mixtures. A catalyst loading of 5% is sufficient for converting even heterocycles prone to electrophilic aromatic substitution. In most cases, however, it is possible to reduce the catalyst content to 1% without significant loss of ee; for example isopropyl cinnamate (Figure 4, entry 1) gave 96% ee and 51% yield after 24 h. It is also usually possible to reduce the excess of the chlorinated salt of the heterocyclic amine to two equivalents.

Claims

What is claimed is:
1. An improved method for converting an olefin to a ╬▓-aminoalcohol using an osmium catalyzed asymmetric aminohydroxylation reaction, wherein the improvement comprises:
in said catalytic asymmetric aminohydroxylation reaction, the olefin is enantioselectively aminohydroxylated using chiral ligands and an N-halo alkali salt of an amino-substituted heterocycle as a nitrogen source for producing the ╬▓- aminoalcohol, the amino group of the amino-substituted heterocycle being oxidized to form the N-halo alkali salt, the heterocycle of the amino-substituted heterocycle including a ring imine conjugated with the amino group to form a planar imidamide system, the ╬▓-aminoalcohol produced by said catalytic asymmetric aminohydroxylation reaction having a ╬▓-amino group substituted with the heterocycle;
wherein the N-halo alkali salt of the amino-substituted heterocycle is represented by the following structure:
Figure imgf000011_0001
wherein X is a halogen, Z+ is an alkali counter ion, -(Ν-X)" Z+ represents the N- halo alkali salt, Ν=C represents the ring imine, N=C-N represents the planar imidamide system, Y together with the ring imine forms the heterocycle, and -R1 is one or more radicals, each independently selected from the group consisting of hydrogen, halogen, aryl, and alkyl groups;
with a proviso that Y does not include a fused imidazole ring coplanar with the planar imidamide system.
2. An improved method for converting an olefin to a ╬▓-aminoalcohol according to claim 1 wherein the N-halo alkali salt of the amino-substituted heterocycle is obtained by activation of amino-substituted heterocycles selected from the following group:
Figure imgf000012_0001
wherein each R is independently selected from a group consisting of hydrogen, halogen, alkyl, and aryl or, together with an adjacent R group, forms a fused aromatic ring.
PCT/US1999/018998 1998-08-21 1999-08-20 Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles WO2000010977A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56822/99A AU5682299A (en) 1998-08-21 1999-08-20 Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9743898P 1998-08-21 1998-08-21
US60/097,438 1998-08-21

Publications (2)

Publication Number Publication Date
WO2000010977A1 true WO2000010977A1 (en) 2000-03-02
WO2000010977A9 WO2000010977A9 (en) 2000-12-14

Family

ID=22263347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/018998 WO2000010977A1 (en) 1998-08-21 1999-08-20 Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles

Country Status (2)

Country Link
AU (1) AU5682299A (en)
WO (1) WO2000010977A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108713A2 (en) * 2005-04-14 2006-10-19 Schering Aktiengesellschaft 1-amino-1, 2,3,4-tetrahydro-naphthaline-2-ol derivates as anti-inflammatory agents
EP1878717A1 (en) * 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7659297B2 (en) 2003-10-08 2010-02-09 Bayer Schering Pharma, AG Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7880042B2 (en) 2006-03-15 2011-02-01 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, methods for the production thereof, and the use thereof as antiphlogistics
EP2327700A1 (en) * 2009-11-21 2011-06-01 Bayer CropScience AG Dialkyl triazinamines and use thereof for combating undesired plant growth
US8097627B2 (en) 2004-04-05 2012-01-17 Bayer Pharma AG Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US8394958B2 (en) 2007-11-22 2013-03-12 Bayer Pharma AG 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
US8987504B2 (en) 2010-06-18 2015-03-24 Victoria Link Limited Aminohydroxylation of alkenes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DRESS K.R. ET AL: "Catalytic Aminohydroxylation Using Adenine-Derivatives as the Nitrogen Sources", TETRAHEDRON LETTERS, vol. 39, 1998, pages 7669 - 7672, XP002922720 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7659297B2 (en) 2003-10-08 2010-02-09 Bayer Schering Pharma, AG Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US8097627B2 (en) 2004-04-05 2012-01-17 Bayer Pharma AG Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
WO2006108713A3 (en) * 2005-04-14 2006-12-14 Schering Ag 1-amino-1, 2,3,4-tetrahydro-naphthaline-2-ol derivates as anti-inflammatory agents
WO2006108713A2 (en) * 2005-04-14 2006-10-19 Schering Aktiengesellschaft 1-amino-1, 2,3,4-tetrahydro-naphthaline-2-ol derivates as anti-inflammatory agents
US7880042B2 (en) 2006-03-15 2011-02-01 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, methods for the production thereof, and the use thereof as antiphlogistics
US8173676B2 (en) 2006-07-14 2012-05-08 Bayer Pharma AG Benzyl, amines, a process for their production and their use as anti-inflammatory agents
EA015258B1 (en) * 2006-07-14 2011-06-30 Байер Шеринг Фарма Акциенгезельшафт Benzyl amines, a process for their production and their use as anti-inflammatory agents
US7999108B2 (en) 2006-07-14 2011-08-16 Bayer Schering Pharma Ag Benzyl amines, a process for their production and their use as anti-inflammatory agents
WO2008006627A1 (en) * 2006-07-14 2008-01-17 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
EP1878717A1 (en) * 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
US8461346B2 (en) 2006-07-14 2013-06-11 Bayer Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
US8394958B2 (en) 2007-11-22 2013-03-12 Bayer Pharma AG 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
US8680117B2 (en) 2007-11-22 2014-03-25 Bayer Schering Pharma Ag 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
USRE47047E1 (en) 2007-11-22 2018-09-18 Astrazeneca Ab 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
EP2327700A1 (en) * 2009-11-21 2011-06-01 Bayer CropScience AG Dialkyl triazinamines and use thereof for combating undesired plant growth
US8987504B2 (en) 2010-06-18 2015-03-24 Victoria Link Limited Aminohydroxylation of alkenes

Also Published As

Publication number Publication date
WO2000010977A9 (en) 2000-12-14
AU5682299A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
Chuentragool et al. General, mild, and selective method for desaturation of aliphatic amines
Grange et al. Recent developments in asymmetric allylic amination reactions
Blank et al. An efficient method for the selective Iridium‐catalyzed monoalkylation of (hetero) aromatic amines with primary alcohols
JP5738185B2 (en) Process for preparing amines from alcohols and ammonia
WO2000010977A1 (en) Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles
Goossen et al. Catalytic Asymmetric Aminohydroxylation with Amino‐Substituted Heterocycles as Nitrogen Sources
Banik et al. Samarium-induced iodine-catalyzed reduction of imines: synthesis of amine derivatives
Park et al. A general strategy for the synthesis of indoloquinolizine alkaloids via a cyanide-catalyzed imino-Stetter reaction
Bartoccini et al. Total synthesis of (−)-clavicipitic acid via γ, γ-dimethylallyltryptophan (DMAT) and chemoselective C–H hydroxylation
SK284369B6 (en) Bisphosphine derivatives, their complexes and method of production of bisphosphine derivatives
CN109096174A (en) A kind of synthetic method of unsubstituted [60] fulleropyrrolidine derivative of N- alkyl -2,5-
Kiselyov A novel three-component reaction of N-fluoropyridinium salts: a facile approach to imidazo [1, 2-a] pyridines
Vyskočil et al. On the ‘Novel two-phase oxidative cross-coupling of the two-component molecular crystal of 2-naphthol and 2-naphthylamine’
CN108640944B (en) Conjugated eneyne amide compounds and preparation method and application thereof
Stolle et al. Intramolecular Diels-Alder reactions of pyrimidines and a computational study toward their structure and reactivity
CN113004248B (en) Method for synthesizing carbazole compound by catalyzing hydrocarbon amination reaction with cobalt
US10995056B2 (en) Direct C—H amination and aza-annulation
CN107298683B (en) A kind of synthetic method of chirality benzodiazepine * compound
CN115197145B (en) Chiral spiro ammonium salt compound and preparation method and application thereof
CN101090881A (en) Process
Kuliukhina et al. CuI and Copper Nanoparticles in the Catalytic Amination of 2-Halopyridines
Doğan et al. PFAM catalyzed enantioselective diethylzinc addition to imines
Zhou et al. Substitution‐type Electrophilic Amination Using Hydroxylamine‐Derived Reagents
Cho et al. Ruthenium‐Catalyzed synthesis of quinolines from anilines and N‐allylic compounds by cascade amine exchange reaction‐heteroannulation
CN102718714B (en) Anthracene-bridged tetradentate imidazole salt and preparation method and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase